BioHarvest CEO to present at H.C. Wainwright event

BioHarvest Sciences Inc. (BHST) reported that Chief Executive Officer Zaki Rakib will present at the H.C.

Rhea-AI Filing Summary

BioHarvest Sciences Inc. (BHST) reported that Chief Executive Officer Zaki Rakib will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City, held September 14-16, 2026. The in-person company presentation is scheduled for September 15, 2026, at 4:00 PM local time.

Rakib will also participate in one-on-one investor meetings during the conference. He highlighted recent “major advancements” in the company’s CDMO research and development programs, including securing its first manufacturing and supply agreement, and plans to discuss progress and opportunities related to BioHarvest’s botanical synthesis platform.

The presentation will be accessible via a publicly available live webcast, with in-person attendance requiring conference registration. BioHarvest describes itself as a leader in Botanical Synthesis, using a patented technology platform to grow plant-based compounds for CDMO projects and proprietary nutraceutical health and wellness products.

Filing Explained

The filing reports that BioHarvest has secured its first manufacturing and supply agreement, but cautions that signed agreements may not proceed past a contracted stage; commercialization and royalties are not assured.

Key Figures

Conference dates: September 14-16, 2026 Presentation date and time: September 15, 2026 at 4:00 PM Exchange listings: Nasdaq: BHST; TASE: BHST; FSE: 8MV0

3 metrics

Conference dates September 14-16, 2026 H.C. Wainwright 28th Annual Global Investment Conference schedule

Presentation date and time September 15, 2026 at 4:00 PM BioHarvest CEO in-person presentation slot at the conference

Exchange listings Nasdaq: BHST; TASE: BHST; FSE: 8MV0 Trading symbols mentioned for BioHarvest Sciences

Key Terms

Botanical Synthesis, contract development and manufacturing organization (CDMO), forward-looking statements

3 terms

Botanical Synthesis technical

"a leader in Botanical Synthesis technology and sustainable plant-based molecule"

Botanical synthesis is the lab-based creation or replication of plant-derived compounds, either by chemically building the molecules or by using engineered organisms to produce them, like recreating a recipe in a factory instead of harvesting from a garden. For investors it matters because it can lower costs, secure supply, protect patents, and affect regulatory review and market access for products that rely on consistent, scalable plant ingredients.

contract development and manufacturing organization (CDMO) financial

"within two major business verticals; as a contract development and manufacturing"

A contract development and manufacturing organization (CDMO) is a company that develops and produces drugs, vaccines or other medical products for other firms, handling steps from formulation and testing to large-scale manufacturing and quality control. Investors care because CDMOs function like outsourced specialized factories and development partners: their revenue grows when many clients need production capacity or development expertise, so their performance signals broader industry demand and is tied to regulatory approvals and client programs.

forward-looking statements regulatory

"This news release contains forward-looking statements within the meaning"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioHarvest Sciences (BHST) announce in this Form 6-K?

BioHarvest Sciences announced that CEO Zaki Rakib will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City, participate in one-on-one investor meetings, and discuss recent advancements in its CDMO programs and botanical synthesis platform.

When and where will BHST present at the H.C. Wainwright conference?

BioHarvest’s presentation is scheduled for September 15, 2026, at 4:00 PM at the Lotte New York Palace Hotel in New York City, in the Roswell (4th Floor) room, as part of the September 14-16, 2026 conference.

How can investors access BioHarvest Sciences’ (BHST) conference presentation?

Investors can access a public live webcast via the provided link, while in-person attendance requires conference registration. Registered in-person and virtual attendees may request one-on-one meetings with BioHarvest management through their H.C. Wainwright representative.

What business focus did BHST highlight in this announcement?

BioHarvest highlighted its role as a leader in Botanical Synthesis, using a patented platform to grow plant-based compounds for two verticals: CDMO services for customers seeking novel plant-based compounds and proprietary nutraceutical health and wellness products.

What forward-looking statement cautions did BioHarvest Sciences (BHST) include?

BioHarvest stated that its news release contains forward-looking statements subject to risks and uncertainties, noting there is no assurance that signed research, manufacturing, or supply agreements will advance or that developed compounds will be commercialized or generate royalties.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 05:11 PM Accepted by SEC EDGAR 09/14/2026 - 05:05 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission file number: 001-42389

BIOHARVEST SCIENCES INC.

(Exact name of Registrant as specified in its charter)

Not applicable

(Translation of Registrant’s name into English)

1140-625 Howe Street, Vancouver, British Columbia V6C 2T6, Canada

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☐ Form 20-F ☒ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

SUBMITTED HEREWITH

Exhibits:

Exhibit	Description
99.1	News Release dated September 14, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOHARVEST SCIENCES INC.
	(Registrant)
Date: September 14, 2026	/s/ David Ryan
	Name: David Ryan
	Title: Vice-President, Investor Relations & Secretary

BioHarvest Sciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. – September 14, 2026) - BioHarvest Sciences Inc (Nasdaq: BHST) (TASE: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will present at the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-16, 2026, in New York City, NY. In addition to presenting, Dr. Rakib will also participate in one-on-one investor meetings throughout the conference.

CEO Zaki Rakib commented “We have recently announced several major advancements in our CDMO research and development programs, which includes securing our first manufacturing and supply agreement. The H.C. Wainwright Global Investment Conference is perfectly timed for me to connect face to face with the New York investment community, and to discuss both the progress already made, and the opportunity presented by our botanical synthesis platform.“

Presentation Details:

•Date/Time: Tuesday, September 15, 2026, at 4:00 PM ET  

•Presenter: Zaki Rakib, Chief Executive Officer 

•Format: In-Person Company Presentation 

•Location: Roswell (4th Floor) | Lotte New York Palace Hotel | New York, NY 

•Webcast link: https://journey.ct.events/view/1c0f3f56-f6fb-4f60-9960-1a0101f9b80f  

The live webcast is publicly accessible for all online investors, and conference registration is mandatory for in-person participation. In-person and virtual registered conference attendees are invited to request a one-on-one meeting with BioHarvest management through their H.C. Wainwright representative.

Investors who are unable to attend the conference and would like to schedule a meeting with BioHarvest management may contact info@bioharvest.com.

About BioHarvest

BioHarvest (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products based on its botanical synthesis technology. To learn more, please visit www.bioharvest.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on management's current expectations, beliefs, and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. There is no assurance that signed research, manufacturing, or supply agreements will proceed past a contracted stage, or that a developed molecule or compound will be commercialized or will generate royalties to the Company. Successful commercialization of any compound  is subject to consumer preferences, advertising budgets and other factors affecting market acceptance of new products which are uncertain and cannot be assured. Readers are cautioned not to place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by applicable law. Additional information is contained in the Company's SEC filings, available at http://www.sec.gov.

BioHarvest Company Contact

Dave Ryan, VP Investor Relations

(604) 622-1186

info@bioharvest.com

Investor Relations Contact:

Chuck Padala, Managing Director

LifeSci Advisors

chuck@lifesciadvisors.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 NEWS RELEASE DATED SEPTEMBER 14, 2026 9.3 KB